atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment ... [+] landscape by working with psychedelic and non-psychedelic compounds.
atai is one of the leading companies that is transforming the landscape of mental health using psychedelics. The company's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds.
Currently, there are a number of treatments that are in development, some of which include MDMA for PTSD and ibogaine for opioid use disorder, alongside psilocybin (the active ingredient in magic mushrooms) and ketamine both for treatment-resistant depression.
Its part of an industry that is gaining a huge amount of interest and influence not only on the stock market, but amongst the wider public, regulators and politicians alike. Atai has also had a number of celebrity investors including the likes of Liam Payne, Diplo and Steve Bartlett who have all come out to show their support for the company.
I caught up with Co-Founder and CEO Florian Brand to find out more about his journey and the launch of the new atai Impact program.
For Part One of This Story, Click Here.
Afdhel Aziz:What are some of the treatments in development you are most excited about?
Florian Brand: It is of course difcult to pick a favorite. We anticipate 18 milestones for our platform companies through the end of 2022. The density of newsow is a result of our decentralized operating model combining aggressive business development with strong inhouse expertise of CNS drug development that have led to our extensive pipeline.
Were expecting several important milestones through the end of this year too. Perhaps the most anticipated for the psychedelic landscape is COMPASS Pathways Phase 2b study for psilocybin therapy for treatment resistant depression, which is expected to provide topline results in Q4 of this year. Psilocybin is derived from mushrooms, hence the term magic mushrooms, which have been used in various cultures around the world going back thousands of years.
Psilocybin has been extensively studied, both in work from the 1960s and, more recently, though ~50 years were lost due to prohibitions enacted around 1970. The data readout from COMPASS is indeed a major event for the whole industry, as this represents the worlds largest psilocybin therapy study, having completed psilocybin administration to 233 treatment resistant depression patients across 22 sites in 10 countries.
A second major milestone; we expect Recognify Life Sciences Phase 2a biomarker trial to have data by the end of the year for cognitive impairment associated with schizophrenia. This is another major indication for us. There are approximately 21 million people in the world who live with schizophrenia, and about 84% of schizophrenia patients suffer from signicant cognitive impairment.
Another 2021 milestone we anticipated and have already achieved is the initiation of a Phase 2 trial of R-ketamine for treatment of resistant depression. Ketamine, including the approved nasal spray with
S-ketamine, has helped people living with severe depression. We believe our approach with R-ketamine has the potential to be another major step in improving the treatment landscape in this much needed area. Our aim is to investigate the potential of this compound as the rst rapid-acting antidepressant approved for at home use due its putatively non-dissociative prole at effective doses.
A further key trial initiation was the recent launch of a Phase 1/2 opioid use disorder trial with ibogaine. Ibogaine is a naturally-occurring, psychedelic compound isolated from a West African shrub, that has demonstrated anecdotal pre-clinical potential of rapid and sustained efcacy in treating opioid use disorder.
Its hard to overstate the devastating effect of the opioid epidemic, which has only been worsened by the COVID-19 pandemic according to the CDCs numbers for 2020, drug overdose deaths shot up ~30% with close to 93,000 deaths, nearly 70,000 of which involved opioids.
Addiction is a complicated issue, but a key part we hope to address is the fact that it appears that current treatments simply arent good enough. With existing therapies, 75% of patients undergoing opioid use disorder therapy experience relapse within just 1 year. So, we desperately need new, better treatments.
Id also point to our efforts in anxiety disorders, which represent the most common mental health disorders in the US, with around 40 million people living with anxiety. It is personal for me, having suffered from debilitating anxiety when I was younger.
Our compound, GRX-917, is an oral formulation of a deuterated version of etifoxine, a compound that has a long history of prescription use in France for treating anxiety disorders. GRX-917 offers the promise, which our clinical trials will robustly assess, to provide rapid anxiolytic activity for potentially improved tolerability to current treatments for anxiety. We launched a Phase 1 trial in generalized anxiety disorder in the rst half of 2021.
"We have a bold vision, to heal mental health disorders so that everyone everywhere can live a more ... [+] fullled life." - Florian Brand, Co-Founder and CEO of atai
Aziz:Please tell us more about this idea of treating the patient and not the disease - by tailoring the experience using digital biomarkers?
Brand: We think that digital therapeutics (DTx) offers interesting applications as part of the treatment paradigm in mental health.
DTx has the potential to provide a more personalized, scalable treatment to those who might not otherwise be able to access high-quality psychological care and/or be limited in the benets received by current treatments. A major limitation to high-quality care is simply geography many patients live far away from treatment centers. And we envision DTx increasing access through tools like remote monitoring and counseling.
So, we plan to tightly integrate a digital strategy from the very beginning of development on a shared architecture across all compounds on atais platform. With digital biomarkers, clinicians may be able to predict patients recovery pathways, limiting trial and error, while streamlining therapeutic impact and better tailoring this to the individual.
With these tools, we intend to move towards precision psychiatry and personalized care which may help therapists to make the best decisions for their patients, meeting patients on their own terms. By using a variety of such digital biomarkers, we hope to make treatments increasingly rened, effective, and individualized.
Aziz:Finally, please tell me a little about atai Impact and its focus?
Brand: Today, we launch atai Impact, our philanthropic program established to support and collaborate with nonprofits and institutions that share atai Life Sciences' vision: to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
AtaiImpact has been developed to harness the power of innovative mental health approaches for positive social change. It will operate to advance education, expand access, and support the wider ecosystem.
It is part of our belief that a for-profit model is the best means of unlocking new modalities for patients in need, however, we recognize that commercial and non-profit entities standing shoulder to shoulder is the ideal way forward.
Through education, we want to help destigmatize mental health, promote better understanding of the potential of psychedelics in mental health care, and foster the next generation of neuro-innovators. By expanding access atai Impact aims to support equal access to innovative and effective mental health support, for everyone, everywhere, regardless of geography or demographics. Furthermore, the program will support the wider ecosystem by contributing to the sustainability of diverse stakeholder communities and environments, including indigenous resources.
The atai Impact program will initially be funded by 1% of the gross proceeds from atai Life Sciences June 2021 IPO and founders contributions. We have also created a Volunteer Paid Time Off Policy, equal to 1% of employees time, and are working with the Equity for Impact initiative to encourage employees and investors to donate a portion of their equity to charitable endeavors. We have been moved by the positive response and level of active support, both at atai and across our external stakeholders, and look forward to the many meaningful initiatives atai Impact will look to support.
The launch of this program marks a very proud moment for everyone at atai and provides us with another means of addressing the escalating mental health crisis.
Read the original post:
How Atai Is Transforming The Landscape Of Mental Health Using Psychedelics (Part 2) - Forbes
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]